

XII SYMPOSIUM INTERNATIONAL

SANTIAGO BREAST CANCER

MARCH 30,31 AND APRIL 1ST; 2020

CENTRO PARQUE - SANTIAGO OF CHILE



PROGRAM

Monday 30, AM

08:45 - 09:00 Welcome Torres, Reyes, Paredes

Breast cancer patient quality of life

09:00 - 09:30 Dealing with vaginal atrophy. **Marco A. Levancini, MD**

08:30 - 09:50 Self-image after breast cancer surgery and reconstruction. **Dr. Octavio Rojas**

09:50 - 10:10 Management of lifestyle risk factors for breast cancer. **Maria J. Escaffi, MD**

- Body mass index

- Physical activity

10:10 - 10:30 Bone density and breast cancer treatment. **Brantes, MD.**

10:30 - 11:00 Coffee break

11:00 - 11:30 Plenary Conference: Lymphoedema after treatment of Breast Cancer: New approaches and Risk factors. **Alphonse Taghian, MD.**

11:30 - 11:50 Surgical management of lymphoedema. **Nicolás Pereira, MD.**

11:50 - 12:20 Plenary Conference: Breast cancer screening. New advances.

Christopher Comstock, MD.

12:30 - 14:00 AstraZeneca Symposium

Monday 30 th PM

Hereditary breast cancer management

14:00 - 14:20 Incorporating low-risk alleles for improve accuracy in breast cancer risk.

14:20 - 14:40 What do we have to recommend when a mutation in a moderate risk gene is found Genetic modifiers of BRCA1/2: Are we ready for polygenic risk score in the BRCA carrier clinic? **Joan Brunet, MD.**

14:40 - 15:00 Telemedicine as a tool for teaching hospitals and community hospitals to improve genetic testing in low income populations. **Nuñez, MD.**

15:00 - 15:20 Tumor testing versus germline testing: When the genetic germline study is indicated after the detection of a pathogenic tumor variant. **Joan Brunet, MD.,**

15:20 - 15:50 Screening and follow up in high risk population **Christopher Comstock, MD.**

15:50 - 16:10 Coffee break

16:10 - 16:20 Managing breast cancer risk after ovarian cancer in a BRCA mutation carriers.

Joan Brunet, MD.

16:20 - 16:50 Breast cancer pathology, treatment and outcome in ATM, BRCA1, BRCA 2, CHECK 2 and PALB2 mutation carriers.

16:50 - 17:10 Legal, ethical and confidential aspects of genetic testing in Latin America.

Dr. Lina Nuñez.

17:10 - 17:30 Genetic Testing for All Patients with Breast Cancer? Must we follow the ASBrS guidelines?

17:30 - 17:50 Risk assessment models what is known and what is new (BOADICEA, Tyrer-Cuzik) **Juan M. Donaire, MD.**

17:50 - 18:05 Round table. Discussion

16:10 - 17:30 AstraZeneca Work - shop (by invitation only)

Tuesday March 31 st , AM

DCIS mini symposium

- 08:30 - 08:50 Pathology as an instrument for selective management of DCIS.
Vicente Peg, MD.
- 08:50 - 09:10 Advances in the management of DCIS. Surgeon
- 09:10 - 09:30 Could we omit radiotherapy in patients with DCIS? **Alphonse Taghian, MD.**
- 09:30 - 10:20 Best submitted abstracts
- 10:20 - 10:35 Invited discussant
- 10:35 - 10:55 Coffee break

Endocrine Positive Disease

- 10:55 - 11:15 Role of pathology to plan endocrine therapy **Vicente Peg, MD.**
- 11:15 - 11:35 Chemotherapy or endocrine neoadjuvant therapy for luminal breast cancer.
Mothaffar Rimawi, MD.
- 11:35 - 11:55 Novel drugs for neoadjuvant endocrine therapy. Are ready for clinical use?
Aleix Prat, MD.
- 10:55 - 11:15 Coffee break
- 11:15 - 11:35 Molecular platforms for adjuvant cancer treatment. Which patients really benefits from them? **Vicente Peg, MD.**
- 11:35 - 11:55 Which agent and how long do we have to use for endocrine adjuvant therapy.
Mothaffar Rimawi , MD.
- 12:00 - 13:00 Early Breast cancer clinical cases discussion. **Cesar Sanchez, MD.**
- 13:00 - 14:30 Industry Symposium with lunch. MSD

Tuesday March 31 st , PM

- 14:30 - 14:50 Cyclin inhibitors for the luminal metastatic breast cancer.
Mothaffar Rimawi, MD.
- 14:50 - 15:10 New drugs not cyclin inhibitors for the endocrine treatment of metastatic breast cancer. **Aleix Prat, MD.**
- 15:10 - 15:30 Treating metastatic luminal breast cancer patient: Is chemotherapy still an option? **Ana Lluich, MD.**
- 15:30 - 15:50 Coffee break
- Triple Negative Disease**
- 15:50 - 16:10 Any news in pathology of triple negative disease? How do we select patients for check points inhibitors? **Vicente Peg, MD.**
- 16:10 - 16:30 Preoperative medical treatment for triple negative disease: Advances in the last two years? **Mafalda Oliveira, MD.**
- 16:30 - 17:30 Best submitted abstracts.
- 17:10 - 17:25 Invited discussant
- 17:25 - 17:50 Determining response after neoadjuvant treatment: role of MRI and core biopsy. **Christopher Comstock, MD.**

Wednesday April 1 st , AM

- 08:30 - 08:50 Triple negative patient with residual disease after neoadjuvant treatment: only capecitabine or something new? **Jennifer K. Littton , MD.**
- 08:50 - 09:10 Role of platinum salts in the neoadjuvant and metastatic triple negative disease. **Mafalda Oliveira,MD.**
- 09:10 - 09:30 Whose patients benefit from immune therapy with check-point inhibitors? When and for whom are they indicated? **Ana Lluch, MD.**
- 09:30 - 09:50 PARP inhibitors and beyond. **Jeniffer Litton, MD.**
- 09:50 - 10:20 Best submitted abstract
- 10:20 - 10:30 Invited discussant
- 10:30 - 10:50 Coffee break
- 10:50 - 11:10 The pathology of HER-2 disease. **Vicente Peg, MD.**
- 11:10 - 11:30 Neoadjuvant treatment for HER – 2 positive disease. Update of the data. Could we avoid chemotherapy? **Aleix Prat, MD.**
- 11:30 - 11:50 Management of the patient ERBB-2 positive disease with residual disease after neoadjuvant treatment: With hormonal receptors positive and with hormonal receptor negative. To be determined
- 11:50 - 12:10 Adjuvant treatment for HER-2 positive disease. How many and which agents? **Hope Rugo, MD.?**
- 11:30 - 11:50 Advanced or metastatic HER-2 positive: actual treatment and new advances To be determined
- 11:50 - 12:10 Radiotherapy of the axilla: After adjuvant and neoadjuvant treatment. **Alphonse Taghian, MD.**
- 12:10 - 13:10 Advanced breast cancer clinical cases discussion. **Roberto Torres, MD.**
- 13:10 - 14:30 Industry symposium
- 14:30 - 15:10 Debate: We always have to dissect the axilla after preoperative medical treatment with clinically positive axilla.
- 14:30 - 14:35 Clinical case presentation
- 14:35 - 14:50 PRO **Augusto Leon, MD.**
- 14:50 - 15:05 CON MSKCC
- 15:05 - 15:15 Plenary discussion (all)
- 15:45 - 16:05 De-escalating radiotherapy: hypofractionation and partial breast irradiation. **Alphonse Taghian, MD.**
- 16:05 - 16:30 Coffee break
- 16:30 - 16:50 Best submitted abstract award, **Reyes, Paredes, Torres y Pfizer representative.**
- 16:50 - 17:10 Prothesis associated lymphoma. **Edward Chang, MD.**
- 16:10 - 17:30 Is it possible to perform conservative surgery in patients with multifocal/multicentric synchronic ipsilateral cancers? To be determined
- 17:30 - 17:50 Reconstruction after conservative surgery. **Edward Chang, MD.**